AstraZeneca Pharma India CFO Bhavana Agrawal Resigns Effective August 31

BENGALURU, India — Pharmaceutical enterprise AstraZeneca Pharma India Limited (NSE: ASTRAZEN, BSE: 500875) announced that Chief Financial Officer (CFO) and Whole-Time Director Bhavana Agrawal has tendered her resignation. Agrawal will remain in her position through the close of business hours on August 31, 2026, to facilitate an orderly leadership transition.

The official departure notice was formally disclosed to domestic stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Executive Profile and Transition Mandate

Bhavana Agrawal, a rank-holding Chartered Accountant with over two decades of global corporate finance experience across multiple markets, assumed the executive role of CFO at AstraZeneca Pharma India in early 2024 before being appointed Whole-Time Director. Prior to joining AstraZeneca, she spent over twelve years holding senior financial leadership positions within General Electric (GE) across the Middle East, Africa, and Russia.

During her tenure, Agrawal oversaw financial strategy, commercial P&L management, and capital allocation across AstraZeneca's expanding specialty healthcare, oncology, and biopharmaceutical portfolio in India. The board of directors confirmed that the company has initiated a structured search process to appoint a replacement CFO.

Organizational Context and Strategic Operations

The financial leadership exit follows a period of strong commercial growth for the Bengaluru-headquartered entity. For the fiscal year ended March 31, 2026, AstraZeneca Pharma India reported a 33% year-on-year increase in total operational revenues, reaching ₹22,755.80 million, alongside a dividend recommendation of ₹36 per equity share.

Market analysts indicate that while executive management transitions can induce temporary administrative adjustments, AstraZeneca's core commercial operations in high-value specialty therapies, including oncology and rare diseases, remain strongly supported by its parent entity, AstraZeneca PLC.

Official Sources Section

Regulatory filings, corporate disclosures, and resignation letters submitted under SEBI guidelines are archived on the official investor portals of the National Stock Exchange of India (NSE) and BSE Limited under supervision of the Securities and Exchange Board of India (SEBI), alongside disclosures on the AstraZeneca India Investor Portal.

Quote Section

"According to officials in corporate regulatory disclosures, Ms. Bhavana Agrawal will complete her tenure as Chief Financial Officer and Whole-Time Director through August 31, 2026, allowing the organization to execute a smooth transition while identifying suitable candidate replacements."

Why It Matters

• For Shareholders & Investors: Details the timeline for financial leadership succession following a period of strong revenue expansion and dividend payouts.

• For Institutional Markets: Confirms governance continuity and compliance under SEBI LODR mandates during corporate executive transitions.

• For Healthcare Partners: Assures uninterrupted financial and commercial operations across AstraZeneca's ongoing product distribution networks in India.

Key Facts at a Glance

• Executive: Bhavana Agrawal (CFO and Whole-Time Director).

• Cessation Date: Effective close of business hours on August 31, 2026.

• Reason: Resignation to pursue career opportunities outside the organization.

• Status: Company has initiated a search process for a successor.

Frequently Asked Questions (FAQ)

What is Bhavana Agrawal's effective last day at AstraZeneca Pharma India?

Bhavana Agrawal will remain in her executive position as Chief Financial Officer and Whole-Time Director until the close of business hours on August 31, 2026.

Why is Bhavana Agrawal stepping down as CFO?

According to regulatory filings submitted to stock exchanges, Agrawal submitted her resignation to pursue career opportunities outside the company.

Who will succeed Bhavana Agrawal as Chief Financial Officer?

AstraZeneca Pharma India has initiated a formal talent search to select a successor for the Chief Financial Officer role. The company will announce the new appointment once approved by the Board of Directors.

Source: Official regulatory disclosures filed by AstraZeneca Pharma India Limited with the National Stock Exchange of India (NSE) and BSE Limited pursuant to Securities and Exchange Board of India (SEBI) regulations.